In November, the UK Supreme Court ruled that Warner-Lambert’s patent for a second medical use of pregabalin for the treatment of pain is invalid for insufficiency of disclosure. Sheena Linehan explores the lessons for patent drafting.
Potter Clarkson is delighted to announce that it has joined a limited number of companies in becoming an official affiliate partner of the Graphene Engineering Innovation Centre, a £60 million pound research centre run by the University of Manchester as part of their vision of building a Graphene City.
Second medical use patents have taken a blow with the Supreme Court’s recent ruling in Warner-Lambert v Mylan and Actavis. Sheena Linehan reports on the ruling and considers its impact on the life sciences sector.
Potter Clarkson is delighted to announce its relocation of its London office to new premises from Monday 19 November.
Earlier this week, the Supreme Court handed down its judgment in Warner-Lambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis, holding Warner-Lambert’s patent to be invalid.
Potter Clarkson is delighted to announce that the recently-published Legal 500 2019 survey once again places our trade mark team in Tier 1 and our patent practice has retained its Tier 2 position.